Severe experimental autoimmune encephalomyelitis (EAE) is ameliorated by human olfactory-derived mesenchymal stromal cell transplantation revealing a role for IL-16

Lindsay, S. , Molęda, A., Maclellan, L., Linington, C. , Goodyear, C. and Barnett, S. (2021) Severe experimental autoimmune encephalomyelitis (EAE) is ameliorated by human olfactory-derived mesenchymal stromal cell transplantation revealing a role for IL-16. XV European Meeting on Glial Cells in Health and Disease, 5-9 July 2021. E430-E432. (doi: 10.1002/glia.24036)

Abstract

Bone marrow-derived mesenchymal stromal cells (BM-MSCs) are being tested in the clinic for the treatment of the demyelinating disease, multiple sclerosis (MS) [1, 2]. Their immunomodulatory action, which targets the inflammatory component of the disease, is thought to make them ideal candidates. We have identified mesenchymal stromal cells from the human olfactory mucosa termed, OM-MSCs[3]. These cells have additional properties suitable for repair since they also enhance CNS myelination and skew microglia to an anti-inflammatory phenotype in vitro [4]. Therefore, OM-MSCs may have therapeutic benefits over BM-MSCsin the treatment of MS. In this investigation, we have compared the reparative properties of OM-MSCs to BM-MSCs in vivousing the experimental autoimmune encephalomyelitis (EAE) model. Although, both MSC types were capable of ameliorating disease, if delivered at early disease onset, when administered during established severe disease, only OM-MSCs significantly improved disease outcome. OM-MSCs mediate this action, in part, by a faster closing of the BBB and a reduction in the recruitment of inflammatory cells, which leads to improved remyelination and axonal survival within demyelinated lesions. OM-MSCs also modulated IL-16 secretion of recruited inflammatory cells. Further in vitroinvestigation of IL-16 revealed a novel inhibitory role on OPC differentiation and myelination. Our data suggests that OM-MSCs may have therapeutic benefits over BM-MSCs in the treatment of MS, especially if administered during progressive disease.

• Item Type: Conference or Workshop Item
• Status: Published
• Refereed: Yes
• Glasgow Author(s) Enlighten ID: Barnett, Professor Susan and Lindsay, Dr Susan and Linington, Professor Christopher and Maclellan, Dr Lindsay and Goodyear, Professor Carl
• Authors: Lindsay, S., Molęda, A., Maclellan, L., Linington, C., Goodyear, C., and Barnett, S.
• Subjects: Q Science > Q Science (General); R Medicine > RC Internal medicine > RC0321 Neuroscience. Biological psychiatry. Neuropsychiatry
• College/School: College of Medical Veterinary and Life Sciences > School of Infection & Immunity
• Research Centre: College of Medical Veterinary and Life Sciences > School of Infection & Immunity > Centre for Immunobiology
• ISSN: 0894-1491
• Published Online: 26 June 2021